Cardiex (ASX: $CDX) Milestones Announcement

Cardiex Limited (ASX: $CDX) has successfully completed the HEARTsense Wearable Study, validating the use of its SphygmoCor® biomarker technology in wearables. The study demonstrated the ability to extract vascular biomarkers from a wearable PPG sensor, a key step towards FDA clearance of its CONNEQT Band wearable technology in Q1 FY2025. Additionally, Cardiex has secured a US patent for its CONNEQT Band wearable technology, marking a significant advancement for the health and wellness industry.

Executive Commentary on Milestones

This is a significant achievement for the Company as well as being a game changer for the medical technology industry. Our technology strategy has always been to produce products that can be deployed in medical and consumer settings for clinics, in the home, and when on-the-go. Importantly, it's our focus on medical-grade wearable solutions which distinguishes us from other companies. The HEARTsense Study is a strong validation of that strategy as well as being a key step towards FDA clearance of our CONNEQT Band wearable technology. We are thrilled to announce that Cardiex has secured the first patent of its kind for a wearable technology system, enabling us to both launch our own devices and to forge partnerships and license our technology to other leading brands looking to deploy FDA-cleared, medical grade health solutions.

Summary of Cardiex Milestones

Cardiex (ASX: $CDX) has achieved significant milestones with the successful completion of the HEARTsense Wearable Study and the securing of a US patent for its CONNEQT Band wearable technology. The study demonstrated the ability to extract vascular biomarkers from a wearable PPG sensor, paving the way for FDA clearance of the CONNEQT Band wearable technology. The Company's focus on medical-grade wearable solutions distinguishes it from other companies, positioning it to create a significant opportunity for shareholders in the wearable healthtech space. With the securing of the patent, Cardiex now holds exclusive rights to market, sell, or license its wearable health technology in a number of device formats, reflecting its commitment to pioneering new health monitoring solutions and enhancing its expertise and leadership in wearable technology.